Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 791-801

  Morley Forster, Patricia K ^a,b   Pergolizzi, Joseph V ^c,d,e   Taylor Jr , Robert ^e   Axford Gatley, Robert A ^f   Sellers, Edward M ^g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEMA Research Inc   (United States)

^f Clinical Content and Editorial Services   (United States)

^g DL Global Partners Inc   (Canada)

Author keywords

Chronic pain; Curricular content; Medical education; Opioids; Pain education; Pain knowledge; Physician training; Teaching

Indexed keywords

ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

CHRONIC PAIN; CLINICAL PROTOCOL; DRUG DEPENDENCE; DRUG FORMULATION; DRUG POTENCY; DRUG RESPONSE; HUMAN; LEARNING; LICENSING; MEDICAL EDUCATION; NARCOTIC DEPENDENCE; PAIN; PATIENT CARE; PHYSICIAN ATTITUDE; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL PSYCHOLOGY; TREATMENT DURATION;

EID: 84889255786     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S47192     Document Type: Review

References (90)

1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11(11):1230-1239.
2. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116(2):248-273.
3. Ripamonti CI, Bandieri E, Roila F, Group EGW. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22(Suppl 6):vi69-vi77.
4. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
5. Zhang W, Moskowitz RW, Nuki G, etal. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
6. Chou R, Qaseem A, Snow V, etal. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491.
7. Attal N, Cruccu G, Baron R, etal. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010revision. Eur J Neurol. 2010;17(9):e1113-e1188.
8. Gibler WB, Cannon CP, Blomkalns AL, etal. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (subcommittee on acute cardiac care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Society of Chest Pain Centers. Circulation. 2005;111(20):2699-2710.
9. Mezei L, Murinson BB. Johns Hopkins Pain Curriculum Development Team. Pain education in North American medical schools. J Pain. 2011;12(12):1199-1208.
10. Watt-Watson J, McGillion M, Hunter J, etal. A survey of prelicensure pain curricula in health science faculties in Canadian universities. Pain Res Manag. 2009;14(6):439-444.
11. Dworkin RH, O'Connor AB, Audette J, etal. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3-S14.
12. Zhang W, Nuki G, Moskowitz RW, etal. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through Jan 2009. Osteoarthritis Cartilage. 2010;18(4): 476-499.
13. International Association for the Study of Pain. Core Curriculum for Professional Education in Pain. 3rd ed. Seattle, WA: IASP Press; 2005.
14. Watt-Watson J, Hunter J, Pennefather P, etal. An integrated undergraduate pain curriculum, based on IASP curricula, for six health science faculties. Pain. 2004;110(1-2):140-148.
15. Yanni LM, Priestley JW, Schlesinger JB, Ketchum JM, Johnson BA, Harrington SE. Development of a comprehensive e-learning resource in pain management. Pain Med. 2009;10(1):95-105.
16. Murinson BB, Nenortas E, Mayer RS, etal. A new program in pain medicine for medical students: integrating core curriculum knowledge with emotional and reflective development. Pain Med. 2011;12(2):186-195.
17. Gunderson EW, Coffin PO, Chang N, Polydorou S, Levin FR. The interface between substance abuse and chronic pain management in primary care: a curriculum for medical residents. Subst Abus. 2009;30(3): 253-260.
18. Tauben DJ, Loeser JD. Pain education at the University of Washington School of Medicine. J Pain. 2013;14(5):431-437.
19. Elhwairis H, Reznich CB. An educational strategy for treating chronic, noncancer pain with opioids: a pilot test. J Pain. 2010;11(12): 1368-1375.
20. Accreditation Council for Graduate Medical Education. Program requirements for graduate medical education in pain medicine. Available from: http://www.acgme.org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/sh_multiPainPR707.pdf. Accessed October 1, 2013.
21. Vadivelu N, Mitra S, Hines RL. Undergraduate medical education on pain management across the globe. Virtual Mentor. 2013;15(5):421-427.
22. Unruh A. Teaching student occupational therapists about pain: a course evaluation. Can J Occup Ther. 1995;62(1):30-36.
23. Strong J, Tooth L, Unruh A. Knowledge about pain among newly graduated occupational therapists: relevance for curriculum development. Can J Occup Ther. 1999;66(5):221-228.
24. Wenghofer EF, Wilson L, Kahan M, et al. Survey of Ontario primary care physicians' experiences with opioid prescribing. Can Fam Physician. 2011;57(3):324-332.
25. Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012;27(11):1521-1527.
26. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712-720.
27. Gupta A, Patton C, Diskina D, Cheatle M. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors. Pain Physician. 2011;14(4):383-389.
28. Murinson BB, Gordin V, Flynn S, Driver LC, Gallagher RM, Grabois M; Medical Student Education Sub-committee of the American Academy of Pain Medicine. Recommendations for a new curriculum in pain medicine for medical students: toward a career distinguished by competence and compassion. Pain Med. 2013;14(3):345-350.
29. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007;27(11): 1571-1587.
30. Shaw WS, Means-Christensen AJ, Slater MA, etal. Psychiatric disorders and risk of transition to chronicity in men with first onset low back pain. Pain Med. 2010;11(9):1391-1400.
31. Zastrow A, Faude V, Seyboth F, Niehoff D, Herzog W, Lowe B. Risk factors of symptom underestimation by physicians. J Psychosom Res. 2008;64(5):543-551.
32. Association of American Medical Colleges. Behavioral and social science foundations for future physicians. Available from: https://www.aamc.org/download/271020/data/behavioralandsocialsciencefoundationsforfuturephysicians.pdf. Accessed October 1, 2013.
33. Leo RJ, Pristach CA, Streltzer J. Incorporating pain management training into the psychiatry residency curriculum. Acad Psychiatry. 2003;27(1):1-11.
34. Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005;119(1-3):95-103.
35. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4(2):4-25.
36. Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008;139(1):127-135.
37. Cohen P, Chen H, Crawford TN, Brook JS, Gordon K. Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug Alcohol Depend. 2007; 88(Suppl 1):S71-S84.
38. Green TC, Grimes Serrano JM, Licari A, Budman SH, Butler SF. Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend. 2009;103(1-2):65-73.
39. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry. 2008;30(2):93-99.
40. Morasco BJ, Turk DC, Donovan DM, Dobscha SK. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013;127(1-3):193-199.
41. Rieckmann T, McCarty D, Kovas A, et al. American Indians with substance use disorders: treatment needs and comorbid conditions. Am J Drug Alcohol Abuse. 2012;38(5):498-504.
42. Barkin RL, Barkin SJ. Reexamining the elderly patient's presentation with depression. Prim Care Companion J Clin Psychiatry. 2008;10(5):415-416.
43. Staton LJ, Panda M, Chen I, et al. When race matters: disagreement in pain perception between patients and their physicians in primary care. J Natl Med Assoc. 2007;99(5):532-538.
44. Chen I, Kurz J, Pasanen M, etal. Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med. 2005;20(7):593-598.
45. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10(12): 1187-1204.
46. Jeffery MM, Butler M, Stark A, Kane RL. Multidisciplinary pain program for chronic noncancer pain: Effective Health Care Program technical brief number 8. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2011.
47. McCarberg BH, Stanos S, Williams DA. Comprehensive chronic pain management: improving physical and psychological function (CME multimedia activity). Am J Med. 2012;125(6):S1.
48. Graham GG, Scott KF. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-413.
49. Baron R. Neuropathic pain: a clinical perspective. Handb Exp Pharmacol. 2009;(194):3-30.
50. Seibert K, Zhang Y, Leahy K, etal. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994;91(25): 12013-12017.
51. Afilalo M, Etropolski MS, Kuperwasser B, etal. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee. Clin Drug Investig. 2010;30(8): 489-505.
52. Barkin RL, Iasco AM, Barkin SJ. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV, Cole BE, editors. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. New York, NY: Taylor and Francis; 2005.
53. Hall S, Gallagher RM, Gracely E, Knowlton C, Wescules D. The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. Pain Med. 2003;4(2):125-134.
54. Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 1998;83(6): 1244-1250.
55. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2): 102-112.
56. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2:1248-1250.
57. Hanlon JT, Boudreau RM, Roumani YF, etal. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2009;64(4):492-498.
58. Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatry. 2008;47(7):745-754.
59. Fanoe S, Hvidt C, Ege P, Jensen BG. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051-1055.
60. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27(7):524-528.
61. Angst MS, Buhrer M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology. 2000;92(5):1473-1476.
62. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10(3): 184-186.
63. Guay DR, Awni WM, Findlay JW, etal. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther. 1988;43(1):63-71.
64. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
65. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37(1):17-40.
66. OPANA® ER (oxymorphone hydrochloride) [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals; 2012.
67. Duragesic® (fentanyl transdermal system) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009.
68. MS Contin® (morphine extended release) [prescribing information]. Hazelwood, MO: Mallinckrod; 2010.
69. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-965.
70. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147-159.
71. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.
72. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
73. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
74. Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22(9): 1859-1865.
75. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652-655.
76. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131-146.
77. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Available from: http://nationalpaincentre.mcmaster.ca/opioid/. Accessed October 1, 2013.
78. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57(11):1269-1276.
79. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.
80. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2): 144-156.
81. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
82. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52(9):1081-1087.
83. Sellers EM, Schoedel KA, Romach MK. Update on formulations to deter tampering. Presented at: College on Problems of Drug Dependence 73rd Annual Scientific Meeting; June 18-23, 2011; Hollywood, FL.
84. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
85. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9(1):57-60.
86. Reisfield GM, Webb FJ, Bertholf RL, Sloan PA, Wilson GR. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag. 2007;3(6):333-337.
87. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
88. Agency Medical Directors Group. Interagency on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. Available from: http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Accessed October 1, 2013.
89. Zink J. On final day, Florida lawmakers approve bill to crack down on pill mills. Tampa Bay Times. May 6, 2011. http://www.tampabay.com/news/health/article1168138.ece. Accessed October 22, 2013.
90. US Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). US Department of Health and Human Services. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed October 1, 2013.